drugset
drugset / Trial / NCT05801029

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

NCT05801029 ↗

Phase 2 Active not recruiting 60 enrolled AstraZeneca Parexel · collab
NaSingle-groupOpen-labelTreatment

Summary

This study will assess the safety and efficacy of Osimertinib with Amivantamab as First-line Treatment in Participants with Epidermal Growth Factor Receptor Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).

Timeline

Start
2023-07-18
Primary completion
2027-10-01
Completion
2027-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Amivantamab Monoclonal antibody 1050 mg Intravenous
Subject Amivantamab Monoclonal antibody 1400 mg Intravenous
Subject Osimertinib Small molecule 80 mg Oral

Indications

non-small cell lung carcinoma